203 related articles for article (PubMed ID: 35848578)
1. Revisiting the potential role of BCG and MMR vaccines in COVID-19.
Bayram Z; Musharrafieh U; Bizri AR
Sci Prog; 2022; 105(2):368504221105172. PubMed ID: 35848578
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
Sharma D
Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
[TBL] [Abstract][Full Text] [Related]
3. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
Fidel PL; Noverr MC
mBio; 2020 Jun; 11(3):. PubMed ID: 32561657
[TBL] [Abstract][Full Text] [Related]
4. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
5. Measles, mumps, rubella prevention: how can we do better?
Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
[TBL] [Abstract][Full Text] [Related]
6. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
[TBL] [Abstract][Full Text] [Related]
7. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
8. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
[TBL] [Abstract][Full Text] [Related]
9. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.
Gothefors L; Bergström E; Backman M
Scand J Infect Dis; 2001; 33(7):545-9. PubMed ID: 11515768
[TBL] [Abstract][Full Text] [Related]
11. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study.
La Torre G; Saulle R; Unim B; Meggiolaro A; Barbato A; Mannocci A; Spadea A
Hum Vaccin Immunother; 2017 Aug; 13(8):1879-1883. PubMed ID: 28604255
[TBL] [Abstract][Full Text] [Related]
13. Vaccines for measles, mumps and rubella in children.
Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
[TBL] [Abstract][Full Text] [Related]
14. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
15. Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents.
Kamei K; Miyairi I; Ishikura K; Ogura M; Shoji K; Funaki T; Ito R; Arai K; Abe J; Kawai T; Onodera M; Ito S
J Pediatr; 2018 May; 196():217-222.e1. PubMed ID: 29499990
[TBL] [Abstract][Full Text] [Related]
16. Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
Vizzotti C; Harris JB; Aquino A; Rancaño C; Biscayart C; Bonaventura R; Pontoriero A; Baumeister E; Freire MC; Magariños M; Duarte B; Grant G; Reef S; Laven J; Wannemuehler KA; Alvarez AMR; Staples JE
BMC Infect Dis; 2023 Mar; 23(1):165. PubMed ID: 36932346
[TBL] [Abstract][Full Text] [Related]
17. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
Wellington K; Goa KL
Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
[TBL] [Abstract][Full Text] [Related]
18. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
MMR-161 Study Group
Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
[TBL] [Abstract][Full Text] [Related]
20. Vaccines for measles, mumps and rubella in children.
Demicheli V; Jefferson T; Rivetti A; Price D
Cochrane Database Syst Rev; 2005 Oct; (4):CD004407. PubMed ID: 16235361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
